Click on image to view larger version.

Figure 3 (A) Kaplan-Meier survival estimates in 156 patients with primary pulmonary hypertension (PPH), according to the results of the 6-min walk test (6’ WT) performed after three months of epoprostenol (PGI₂) therapy. Survival rates for patients walking >380 m during the 6’ WT (corresponding to the median value) (solid line) were 99%, 88%, and 81% at one, two, and three years, respectively, as compared with 86%, 64%, and 56% for patients walking <380 m (dashed line) (p = 0.0005 by the Cox-Mantel log-rank test). (B) Kaplan-Meier survival estimates in 156 patients with PPH, according to the change () in the 6’ WT between baseline and three months of PGI₂ therapy. No difference in survival was demonstrated in patients who improved their 6-min walk distance to >112 m (corresponding to the median value) (solid line), as compared with those who did not (dashed line) (p = 0.86 by the Cox-Mantel log-rank test).